<SEC-DOCUMENT>0001193125-23-264201.txt : 20231027
<SEC-HEADER>0001193125-23-264201.hdr.sgml : 20231027
<ACCEPTANCE-DATETIME>20231026173133
ACCESSION NUMBER:		0001193125-23-264201
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20231024
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231027
DATE AS OF CHANGE:		20231026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alphatec Holdings, Inc.
		CENTRAL INDEX KEY:			0001350653
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				202463898
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52024
		FILM NUMBER:		231351274

	BUSINESS ADDRESS:	
		STREET 1:		5818 EL CAMINO REAL
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
		BUSINESS PHONE:		760-431-9286

	MAIL ADDRESS:	
		STREET 1:		5818 EL CAMINO REAL
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d574137d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:atec="http://alphatecspine.com/20231024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2023-10-24_to_2023-10-24">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-10-24_to_2023-10-24">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-10-24_to_2023-10-24">0001350653</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="atec-20231024.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-10-24_to_2023-10-24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001350653</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-24</xbrli:startDate> <xbrli:endDate>2023-10-24</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-10-24_to_2023-10-24">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt:datemonthdayyearen">October&#160;24, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-10-24_to_2023-10-24">ALPHATEC HOLDINGS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-10-24_to_2023-10-24">000-52024</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-10-24_to_2023-10-24">20-2463898</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-10-24_to_2023-10-24">1950 Camino Vida Roble</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-10-24_to_2023-10-24">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-10-24_to_2023-10-24">92008</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-10-24_to_2023-10-24">(760)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-10-24_to_2023-10-24">431-9286</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style=" text-align: center;margin:auto; width:4%;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14.a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-24_to_2023-10-24">Common stock, par value $.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-24_to_2023-10-24">ATEC</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The NASDAQ Global Select Market</span> </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="justify"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:justify">Item&#8201;1.01</p></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On October&#160;24, 2023, Alphatec Holdings, Inc. (the &#8220;Company&#8221;) entered into an Underwriting Agreement, as amended by the First Amendment to Underwriting Agreement, dated October&#160;26 2023 (the &#8220;Underwriting Agreement&#8221;), with Morgan Stanley&#160;&amp; Co. LLC, Cowen and Company, LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to the issuance and sale of 14,300,000 shares of common stock of the Company (the &#8220;Offering&#8221;) at a public offering price of $10.50 per share. Pursuant to the Underwriting Agreement, the Company granted the Underwriters <span style="white-space:nowrap">a&#160;30-day&#160;option</span> to purchase up to an additional 2,145,000 shares of common stock at the public offering price per share, less underwriting discounts and commissions. The Company estimates gross proceeds from the Offering, assuming no exercise of the Underwriters&#8217; option to purchase additional shares and before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company, will be approximately $150&#160;million. The Offering is expected to close on October&#160;27, 2023, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. In addition, pursuant to the terms of the Underwriting Agreement, the executive officers, directors and certain shareholders of the Company have entered into <span style="white-space:nowrap">&#8220;lock-up&#8221;</span> agreements with the underwriters, which generally prohibit the sale, transfer or other disposition of securities of the Company for a <span style="white-space:nowrap">90-day</span> period, subject to certain exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Offering is being made pursuant to the Company&#8217;s effective Registration Statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-217336),</span> including the prospectus dated April&#160;19, 2023, as supplemented by a prospectus supplement dated October&#160;24, 2023. This Current Report on Form <span style="white-space:nowrap">8-K</span> shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The Offering may only be made by means of the prospectus supplement and related base prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing description of the Underwriting Agreement and the First Amendment to the Underwriting Agreement are not complete and are qualified in their entirety by reference to the full text of the Underwriting Agreement and the First Amendment to the Underwriting Agreement, copies of which are filed herewith as Exhibit 1.1 and Exhibit 1.2, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and are incorporated herein by reference. A copy of the opinion of Dentons Durham Jones Pinegar P.C., relating to the legality of the issuance and sale of the shares of common stock in the Offering, is filed as Exhibit 5.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="justify"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:justify">Item&#8201;7.01</p></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On October&#160;24, 2023, the Company issued a press release announcing the pricing of the Offering. The press release is attached as Exhibit 99.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The information in this Item 7.01 is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="justify"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:justify">Item&#8201;9.01</p></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:justify">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">(d)&#8195;&#8194;&#8195;<span style="text-decoration:underline">Exhibits</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">&#8194;1.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d574137dex11.htm">Underwriting Agreement dated October&#160;24, 2023 </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">&#8194;1.2</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d574137dex12.htm">First Amendment to Underwriting Agreement dated October&#160;26, 2023 </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">&#8194;5.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d574137dex51.htm">Opinion of Dentons Durham Jones Pinegar P.C. </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">23.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d574137dex51.htm">Consent of Dentons Durham Jones Pinegar P.C. (contained in Exhibit 5.1) </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">99.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify"><a href="d574137dex991.htm">Press Release of Alphatec Holdings, Inc., dated October&#160;24, 2023 </a></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">104</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Date: October&#160;26, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:justify">ALPHATEC HOLDINGS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">By:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:justify">/s/ J. Todd Koning</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Name:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">J. Todd Koning</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Its:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Chief Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d574137dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>14,300,000 Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALPHATEC HOLDINGS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK, PAR VALUE $0.0001 PER SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;24, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">October&nbsp;24, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan Stanley&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cowen and Company, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Barclays
Capital Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c/o Morgan Stanley&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1585 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10036 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c/o Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">599 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c/o Barclays Capital Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">745 Seventh Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Alphatec Holdings, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several
Underwriters named in Schedule I hereto (the &#147;<B>Underwriters</B>&#148;) 14,300,000 shares of its common stock, $0.0001 par value per share (the &#147;<B>Firm Shares</B>&#148;). The Company also proposes to issue and sell to the several
Underwriters not more than an additional 2,145,000 shares of its common stock, $0.0001 par value per share (the &#147;<B>Additional Shares</B>&#148;), if and to the extent that Morgan Stanley&nbsp;&amp; Co. LLC (&#147;<B>Morgan Stanley</B>&#148;),
Cowen and Company, LLC (&#147;<B>Cowen</B>&#148;), and Barclays Capital Inc. (&#147;<B>Barclays</B>&#148;), as representatives of the several Underwriters (the &#147;<B>Representatives</B>&#148;), shall have determined to exercise, on behalf of the
Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section&nbsp;2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the &#147;<B>Shares</B>.&#148; The shares of
common stock, $0.0001 par value per share of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &#147;<B>Common Stock</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) an automatic shelf
registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-271336),</FONT> which became effective on April&nbsp;19, 2023, including a prospectus, relating to the Shares. The
registration statement, at the time it became effective, including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A under the Securities Act of 1933, as amended (the
&#147;<B>Securities Act</B>&#148;), is hereinafter referred to as the &#147;<B>Registration Statement</B>&#148;; the prospectus in the form first used to confirm sales of Shares (or in the form first made available to the Underwriters by the Company
to meet requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the &#147;<B>Prospectus</B>.&#148; If the Company has filed an abbreviated registration statement to register additional shares of Common
Stock pursuant to Rule 462(b) under the Securities Act (a &#147;<B>Rule 462 Registration Statement</B>&#148;), then any reference herein to the term &#147;<B>Registration Statement</B>&#148; shall be deemed to include such Rule 462 Registration
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this Agreement, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule
405 under the Securities Act, &#147;preliminary prospectus&#148; shall mean each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted information pursuant to Rule 430A under the Securities Act
that was used after such effectiveness and prior to the execution and delivery of this Agreement, &#147;<B>Time of Sale Prospectus</B>&#148; means the prospectus contained in the Registration Statement at the time of its effectiveness together with
the documents and pricing information set forth in Schedule II hereto, and &#147;<B>broadly available road show</B>&#148; means a &#147;bona fide electronic road show&#148; as defined in Rule 433(h)(5) under the Securities Act that has been made
available without restriction to any person. As used herein, the terms &#147;Registration Statement,&#148; &#147;preliminary prospectus,&#148; &#147;Time of Sale Prospectus&#148; and &#147;Prospectus&#148; shall include the documents, if any,
incorporated by reference therein as of the date hereof. The terms &#147;<B>supplement,</B>&#148; &#147;<B>amendment</B>&#148; and &#147;<B>amend</B>&#148; as used herein with respect to the Registration Statement, the Time of Sale Prospectus or the
Prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), that are deemed to be incorporated by reference therein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <I>Representations and Warranties</I>. The Company represents and warrants to and agrees with each of the Underwriters
that: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Registration Statement has become effective; no stop order
suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose or pursuant to Section&nbsp;8A under the Securities Act are pending before or threatened by the Commission. If the Registration Statement is
an automatic shelf registration statement as defined in Rule 405 under the Securities Act, the Company is a well-known seasoned issuer (as defined in Rule 405 under the Securities Act) eligible to use the Registration Statement as an automatic shelf
registration statement and the Company has not received notice that the Commission objects to the use of the Registration Statement as an automatic shelf registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) (i) Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of
Sale Prospectus or the Prospectus complied when it was filed or will comply when so filed, as the case may be, in all material respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, as applicable, in
effect at the time of such filing, (ii)&nbsp;the Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, as of the date of such amendment or supplement, will not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (iii)&nbsp;the Registration Statement and the Prospectus comply and, as amended or supplemented, if
applicable, as of the date of such amendment or supplement, will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder, (iv)&nbsp;the Time of Sale Prospectus does not, and at
the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;4), the Time of Sale Prospectus, as then amended or
supplemented by the Company, if applicable, as of the date of such amendment or supplement, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, (v)&nbsp;each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (vi)&nbsp;the Prospectus, as of its date, does not contain and, as amended or supplemented, if applicable, as of
its date or as of the Closing Date and each Option Closing Date (as defined below) will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon
information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The Company is not an &#147;ineligible issuer&#148; in connection with the offering pursuant to Rules 164, 405 and 433
under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act and
the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or
referred to by the Company complies or will comply, as of the date of such filing, in all material respects with the applicable requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Except for the
free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, each furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the prior
consent of the Representatives, prepare, use or refer to, any free writing prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) The Company has been duly
incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own or lease its property and to conduct its business as described in each of the
Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such
qualification, except to the extent that the failure to be so qualified or be in good standing would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Each subsidiary of the Company has been duly incorporated, organized or formed, is validly existing as a corporation
or other business entity in good standing under the laws of the jurisdiction of its incorporation, organization or formation, has the corporate or other business entity power and authority to own or lease its property and to conduct its business as
described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not, singly or in the
aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock or other equity interests of each subsidiary of the Company have been duly and
validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) The authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of
the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) The shares of Common Stock outstanding
prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) The Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this
Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and the issuance of the Shares will not be subject to any preemptive or similar rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) Except as described in the Registration Statement, in the Time of Sale Prospectus and in the Prospectus, there are no
options, warrants, agreements, contracts or other rights in existence to purchase or acquire from the Company or any subsidiary of the Company any shares of the capital stock of the Company or any subsidiary of the Company. The description of the
Company&#146;s stock option, stock bonus and other stock plans or arrangements (the &#147;<B>Company Stock Plans</B>&#148;), and the options (the &#147;<B>Options</B>&#148;) or other rights granted thereunder, set forth in the Time of Sale
Prospectus and in the Prospectus accurately and fairly presents in all material respects the information required to be shown with respect to such plans, arrangements, options and rights. Each grant of an Option (A)&nbsp;was duly authorized no later
than the date on which the grant of such Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof)
and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto and (B)&nbsp;was made in accordance with the
terms of the applicable Company Stock Plan, and all applicable laws and regulatory rules or requirements, including all applicable federal securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement
will not contravene any provision of (i)&nbsp;applicable law, (ii)&nbsp;the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company, (iii)&nbsp;any agreement or other instrument binding upon the Company or any
of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or (iv)&nbsp;any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, except in the
case of (iii)&nbsp;above, where contravention would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, and no consent, approval, authorization or order of,
or qualification with, any governmental body, agency or court is required for the performance by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various states in
connection with the offer and sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) There has not occurred any material adverse change, or any
development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale
Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m) There are no legal or governmental proceedings pending or, to the Company&#146;s knowledge, threatened to
which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i)&nbsp;other than proceedings accurately described in all material respects in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus and proceedings that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or
ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by each of the Registration Statement, the Time of Sale Prospectus and the Prospectus or (ii)&nbsp;that are required to be
described in the Registration Statement, the Time of Sale Prospectus or the Prospectus and are not so described in all material respects; and there are no statutes, regulations, contracts or other documents that are required to be described in the
Registration Statement, the Time of Sale Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that are not described in all material respects or filed as required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n) Each preliminary prospectus, if any, filed as part of the Registration
Statement as originally filed or as part of any amendment thereto, or filed pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable rules and regulations of the
Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(o) The Company is not, and after giving effect to the offering and sale of the Shares and the
application of the proceeds thereof as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be, required to register as an &#147;investment company&#148; as such term is defined in the Investment
Company Act of 1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(p) The Company and each of its subsidiaries (i)&nbsp;are in compliance with any and all
applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<B>Environmental Laws</B>&#148;),
(ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or
approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the
aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(q) There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or
operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential
liabilities to third parties) which would, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(r) The Company and each of its subsidiaries (A)&nbsp;is in compliance, in all material respects, with any and all applicable
foreign, federal, state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all governmental authorities (including pursuant to the Occupational Health and Safety Act) relating to the protection of human health
and safety in the workplace (&#147;<B>Occupational Laws</B>&#148;); (B) has received all material permits, licenses or other approvals required of it under applicable Occupational Laws to conduct its business as currently conducted; and (C)&nbsp;is
in compliance, in all material respects, with all terms and conditions of such permit, license or approval. No action, proceeding, revocation proceeding, writ, injunction or claim is pending or, to the Company&#146;s knowledge, threatened against
the Company or any of its subsidiaries relating to Occupational Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(s) Except as disclosed in the Time of Sale
Prospectus, the Registration Statement and the Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the
Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Shares registered pursuant to the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(t) (i) None of the Company or any of its subsidiaries or affiliates, or any director, officer, or employee thereof, or, to
the Company&#146;s knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment,
giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) in order to influence official action, or to any person in violation of
any applicable anti-corruption laws; (ii)&nbsp;the Company and each of its subsidiaries and affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to
maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; and (iii)&nbsp;neither the Company nor any of its subsidiaries will use, directly or
indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(u) The operations of the Company and each of its subsidiaries are and have been conducted at all times in material compliance
with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct
Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
laundering statutes of jurisdictions where the Company and each of its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) (i) None of the Company, any of its subsidiaries, or any director, officer, or employee thereof, or, to the Company&#146;s
knowledge, any agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&#147;<B>Person</B>&#148;) that is, or is owned or controlled by one or more Persons that are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of
Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(B) located, organized or resident in a country or territory that is the subject of Sanctions (including,
without limitation, <FONT STYLE="white-space:nowrap">the&nbsp;so-called&nbsp;Donetsk</FONT> People&#146;s Republic, <FONT STYLE="white-space:nowrap">the&nbsp;so-called&nbsp;Luhansk</FONT> People&#146;s Republic, the Crimea Region of Ukraine, Cuba,
Iran, North Korea and Syria). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) The Company will not, directly or indirectly, use the proceeds of the
offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that,
at the time of such funding or facilitation, is the subject of Sanctions; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(B) in any other manner that
will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) For the past 5 years, the Company and each of its subsidiaries have not knowingly engaged in, are not now
knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(w) The Company and each of its subsidiaries owns, possesses, or can acquire on reasonable terms, all Intellectual Property
necessary for the conduct of the Company&#146;s and its subsidiaries&#146; business as now conducted or as described in the Time of Sale Prospectus, the Registration Statement and in the Prospectus to be conducted, except as such failure to own,
possess, or acquire such rights would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. Furthermore, (A)&nbsp;to the knowledge of the Company, there is no infringement,
misappropriation or violation by third parties of any such Intellectual Property, except as such infringement, misappropriation or violation would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries,
taken as a whole; (B)&nbsp;except as disclosed in the Time of Sale Prospectus, the Registration Statement and the Prospectus, there is no pending or, to the knowledge of the Company, threatened in writing, action, suit, proceeding or claim by others
challenging the Company&#146;s or any of its subsidiaries&#146; rights in or to any such Intellectual Property; (C)&nbsp;the Intellectual Property owned by the Company and its subsidiaries, and to the knowledge of the Company, the Intellectual
Property licensed to the Company and its subsidiaries, has not been adjudged invalid or unenforceable, in whole or in part, and, except as disclosed in the Time of Sale Prospectus, the Registration Statement and the Prospectus, there is no pending
or, to the knowledge of the Company, threatened in writing action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property; (D)&nbsp;except as disclosed in the Time of Sale Prospectus, the Registration
Statement and the Prospectus, there is no pending or, to the knowledge of the Company, threatened in writing action, suit, proceeding or claim by others that the Company or any of its subsidiaries infringes, misappropriates or otherwise violates any
Intellectual Property or other proprietary rights of others and neither the Company nor any of its subsidiaries has received any written notice of such claim; and (E)&nbsp;to the Company&#146;s knowledge, no employee of the Company or any of its
subsidiaries is in or has ever been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement,
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company or any
of its subsidiaries or actions undertaken by the employee while employed with the Company or any of its subsidiaries, except as such violation would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries,
taken as a whole. &#147;<B>Intellectual Property</B>&#148; shall mean all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, domain names,
technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) (i) The Company and its subsidiaries use and have used any and all
software and other materials distributed under a &#147;free,&#148; &#147;open source,&#148; or similar licensing model (including but not limited to the MIT License, Apache License, GNU General Public License, GNU Lesser General Public License and
GNU Affero General Public License) (&#147;<B>Open Source Software</B>&#148;) in compliance with all license terms applicable to such Open Source Software, except where such <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, singly or
in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; and (ii)&nbsp;neither the Company nor any of its subsidiaries uses or distributes or has used or distributed any Open
Source Software in any manner that requires or has required (A)&nbsp;the Company or any of its subsidiaries to permit reverse engineering of any software code or other technology owned by the Company or any of its subsidiaries or (B)&nbsp;any
software code or other technology owned by the Company or any of its subsidiaries to be (1)&nbsp;disclosed or distributed in source code form, (2)&nbsp;licensed for the purpose of making derivative works or (3)&nbsp;redistributed at no charge,
except where such permitted reverse engineering, source code disclosure, derivative work or free redistribution would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries,
taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(y) (i) The Company and each of its subsidiaries have complied and are presently in compliance with all
internal and external privacy policies, contractual obligations, applicable industry standards, applicable laws, statutes, judgments, orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority and any
other applicable legal obligations, in each case, relating to the collection, use, transfer, import, export, storage, protection, disposal and disclosure by the Company or any of its subsidiaries of personal, personally identifiable, household,
sensitive, confidential or regulated data (&#147;<B>Data Security Obligations</B>&#148;); (ii) the Company has not received any notification of or complaint regarding and is unaware of any other facts that, individually or in the aggregate, would
reasonably indicate <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation; and (iii)&nbsp;there is no action, suit or proceeding by or before any court or governmental agency, authority or body pending or, to the
Company&#146;s knowledge, threatened alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> by the Company with any Data Security Obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(z) (i)&nbsp;(A) There has been no security breach or other compromise of or relating to any of the Company&#146;s and its
subsidiaries&#146; information technology and computer systems, networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them),
equipment or technology (&#147;<B>IT Systems and Data</B>&#148;) that would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, and (B)&nbsp;the Company and its subsidiaries have not been
notified of, and have no knowledge of any event or condition that would reasonably be expected to result in any security breach, attack or compromise to their IT Systems and Data that would reasonably be expected to have a material adverse effect on
the Company and its subsidiaries, taken as a whole, (ii)&nbsp;the Company and each of its subsidiaries have complied, and are presently in compliance with, in all material respects, all applicable laws, statutes or any judgment, order, rule or
regulation of any court or arbitrator or governmental or regulatory authority and all industry guidelines, standards, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of
such IT Systems and Data from unauthorized use, access, misappropriation or modification and (iii)&nbsp;the Company and each of its subsidiaries have implemented backup and disaster recovery technology reasonably consistent with industry standards
and practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(aa) The Company and its subsidiaries possess, or qualify for applicable exemptions to, such valid and
current registrations, listings, approvals, exemptions, clearances, licenses, certificates, authorizations or permits and supplements or amendments thereto issued or required by the appropriate state, federal or foreign regulatory agencies or bodies
necessary to conduct their business (collectively, &#147;<B>Permits</B>&#148;), including, without limitation, all such Permits required by the United States Food and Drug Administration (the &#147;<B>FDA</B>&#148;), the United States Department of
Health and Human Services (&#147;<B>HHS</B>&#148;), the United States Centers for Medicare&nbsp;&amp; Medicaid Services (&#147;<B>CMS</B>&#148;), the European Medicines Agency (&#147;<B>EMEA</B>&#148;), Health Canada or any other state, federal or
foreign agencies or bodies engaged in the regulation of medical devices (including diagnostic products), drugs, biologics or biohazardous materials. All of the material Permits are valid and in full force and effect, the Company and its subsidiaries
are in material compliance with the terms and conditions of all such Permits, and no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof, or results in any other material impairment of the
rights of the holder of any material Permit. The Company and its subsidiaries have not received any written notice of proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any
Permits, the lack of which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(bb) The Company and its subsidiaries and, to the Company&#146;s knowledge, its directors, employees and agents (while acting
in such capacity) are and have been, since October&nbsp;1, 2020, in material compliance with, all health care </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
laws applicable to the Company, or any of its products or activities, including, but not limited to, the federal Anti-Kickback Statute (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil Monetary Penalties Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a(a)),</FONT> the civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the
criminal false statements law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> the Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> the health care fraud criminal
provisions under HIPAA (as defined below), including 18 U.S.C. Sections 286, 287, 1347 and 1349, the exclusion laws (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
Section&nbsp;301 et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act), each as amended from time to time, the regulations
promulgated pursuant to such laws, and any other state, federal or foreign law, accreditation standards, regulation, memorandum, opinion letter, or other issuance which imposes requirements on the manufacturing, development, testing, labeling,
advertising, marketing or distribution of drugs, biologics and medical devices (including diagnostic products), kickbacks, patient or program charges, recordkeeping, claims process, documentation requirements, medical necessity, referrals, the
hiring of employees or acquisition of services or supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care, medical
devices or diagnostics products or services (collectively, &#147;<B>Health Care Laws</B>&#148;). Neither the Company nor any of its subsidiaries has received any written notification, correspondence or other communication, including notification of
any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental authority, including, without limitation, the FDA, the EMEA, Health Canada, the United States Federal Trade
Commission, the United States Drug Enforcement Administration, CMS, HHS&#146;s Office of Inspector General, the United States Department of Justice and state Attorneys General or similar agencies of potential or actual
<FONT STYLE="white-space:nowrap">non-compliance</FONT> in any material respect by, or material liability of, the Company or any of its subsidiaries under any Health Care Laws. To the Company&#146;s knowledge, there are no facts or circumstances that
would reasonably be expected to give rise to material liability of the Company or any of its subsidiaries under any Health Care Laws. The statements with respect to Health Care Laws and the Company&#146;s compliance therewith included in the Time of
Sale Prospectus, the Registration Statement and in the Prospectus fairly summarize the matters therein described. Since October&nbsp;1, 2020, the Company and its subsidiaries have filed, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring
agreements, deferred or <FONT STYLE="white-space:nowrap">non-prosecution</FONT> agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, none of the Company, any
of its subsidiaries or any of their respective employees, officers, directors, or, to the Company&#146;s knowledge, agents has, since October&nbsp;1, 2020, been or is currently excluded, suspended or debarred from participation in any U.S. federal
health care program or human clinical research or, to the Company&#146;s knowledge, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or
exclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(cc) The Company and its subsidiaries are, and since October&nbsp;1, 2020, have been in material compliance
with all applicable regulatory post-market reporting obligations under any Health Care Laws, including, without limitation, the FDA&#146;s adverse event reporting requirements at 21 CFR Parts 310, 314, 600, and 803, and, to the extent applicable,
the respective counterparts thereof promulgated by governmental authorities in countries outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(dd)
Except as disclosed in the Registration Statement, the Time of Sale Prospectus and in the Prospectus, to the Company&#146;s knowledge, neither the Company nor any of its subsidiaries has had any product, clinical laboratory or manufacturing site
(whether Company-owned or that of a third party manufacturer for the Company&#146;s products) subject to a governmental authority (including FDA) shutdown or import or export prohibition, or received any FDA Form 483 or other governmental authority
notice of inspectional observations, &#147;warning letters,&#148; &#147;untitled letters,&#148; requests to make changes to the Company&#146;s or its subsidiaries&#146; products, processes or operations, or similar correspondence or notice from the
FDA or other governmental authority alleging or asserting material noncompliance with any applicable Health Care Laws. To the Company&#146;s knowledge, neither the FDA nor any other governmental authority is considering such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ee) The Company and its subsidiaries are, and at all times prior hereto have been, in compliance in all material respects
with all applicable state, federal, and international data privacy, security and consumer protection laws and regulations, including, without limitation, applicable requirements of the Health Insurance Portability and Accountability Act of 1996, as
amended by the Health Information Technology for Economic and Clinical Health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Act, and regulations promulgated thereunder (collectively, &#147;<B>HIPAA</B>&#148;); and the Company and its subsidiaries have taken commercially reasonable actions to comply with, and have been
and currently are in compliance in all material respects with, the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679) (collectively, the &#147;<B>Privacy Laws</B>&#148;). To the extent required by the Privacy
Laws, the Company and its subsidiaries have in place and take commercially reasonable steps to comply in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling, and analysis of Personal Data. &#147;<B>Personal Data</B>&#148; means (A)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or
tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or customer or account number; (B)&nbsp;any information which would qualify as &#147;personally identifiable&#148; information as applied
by the Federal Trade Commission; (C) &#147;Protected Health Information,&#148; as defined by HIPAA; (D) &#147;personal data,&#148; as defined by GDPR; and (E)&nbsp;any other information that allows the identification of such natural person, or his
or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual orientation. The Company and its subsidiaries have, at all times prior hereto, made all material disclosures to users or
customers required by applicable Privacy Laws, and none of such disclosures made or contained in any such disclosures have, to the knowledge of the Company, been inaccurate or in violation of any applicable Privacy Laws in any material respect.
Neither the Company nor any subsidiary: (1)&nbsp;has received written notice of any actual or alleged liability, including, but not limited to security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of
Personal Data, under or relating to, or actual or alleged violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected; (2)&nbsp;is currently conducting or paying for, in whole or in part,
any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (3)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ff) (A) Except as disclosed in the Registration Statement, the Time of Sale Prospectus and in the Prospectus, to the
Company&#146;s knowledge, there have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, &#147;dear doctor&#148; letters, investigator notices, safety alerts or other notice of action relating to an
alleged lack of safety, efficacy, or regulatory compliance of the Company&#146;s or any of its subsidiaries&#146; products (&#147;<B>Safety Notices</B>&#148;) and (B)&nbsp;to the Company&#146;s knowledge, there are no facts that would be reasonably
likely to result in (1)&nbsp;a Safety Notice with respect to the Company&#146;s or any of its subsidiaries&#146; products or services, (2)&nbsp;a change in labeling of any the Company&#146;s or any of its subsidiaries&#146; respective products or
services, or (3)&nbsp;a termination or suspension of marketing or testing of any the Company&#146;s or any of its subsidiaries&#146; products or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(gg) The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be
filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries,
taken as a whole) and have paid all taxes required to be paid thereon (except for cases in which the failure to file or pay would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its
subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which reserves required by generally accepted accounting principles (&#147;<B>U.S. GAAP</B>&#148;) have been created in the financial statements of the
Company), and no tax deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate, has had (nor does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency
which could reasonably be expected to be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(hh) The financial statements included or incorporated by reference in each of the Registration Statement, the Time of Sale
Prospectus and the Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the applicable accounting requirements of the Securities Act and present fairly in all material respects the
consolidated financial position of the Company and its subsidiaries as of the dates shown and its results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity with U.S. GAAP applied on a
consistent basis throughout the periods covered thereby except as may be expressly stated in the related notes thereto and for any normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments in the Company&#146;s quarterly financial
statements. The other financial information included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents
fairly in all material respects the information shown thereby. The statistical, industry-related and market-related data included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate and such data is consistent with the sources from which they are derived, in
each case in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) Deloitte&nbsp;&amp; Touche LLP, who has certified certain financial statements
of the Company and its subsidiaries and delivered its report with respect to the audited consolidated financial statements and schedules filed with the Commission as part of the Registration Statement and included in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus, is an independent registered public accounting firm with respect to the Company within the meaning of the Securities Act and the applicable rules and regulations thereunder adopted by the
Commission and the Public Company Accounting Oversight Board (United States). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(jj) The Company and each of its
subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are
recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific
authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement fairly presents the required information in all material respects. Since the end of the Company&#146;s most recent audited fiscal year, there has been (i)&nbsp;no
material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (ii)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially adversely affected, or is
reasonably likely to materially adversely affect, the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(kk) The
Company (i)&nbsp;has not alone engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication with any person other than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representatives with entities that are reasonably believed to be qualified institutional buyers within the
meaning of Rule 144A under the Securities Act or institutions that are reasonably believed to be accredited investors within the meaning of Rule 501 under the Securities Act and (ii)&nbsp;has not authorized anyone other than the Representatives to
engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication that is a written communication within the meaning of Rule 405 under the Securities Act other than those listed on Schedule III hereto.
&#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means any communication with potential investors undertaken in reliance on Section&nbsp;5(d) or Rule 163B of the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ll) As of the time of each sale of the Shares in connection with the offering when the Prospectus is not
yet available to prospective purchasers, none of (A)&nbsp;the Time of Sale Prospectus, (B)&nbsp;any free writing prospectus, when considered together with the Time of Sale Prospectus, and (C)&nbsp;any individual <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the Time of Sale Prospectus, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(mm) Neither the Company nor any of its subsidiaries has any securities rated by any &#147;nationally recognized statistical
rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(nn) The Company
is in compliance with all applicable provisions of the Sarbanes-Oxley Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(oo) The Company maintains disclosure controls and procedures (as defined in Rules
<FONT STYLE="white-space:nowrap">13a-14</FONT> and <FONT STYLE="white-space:nowrap">15d-14</FONT> under the Exchange Act) and such controls and procedures are effective in ensuring that material information relating to the Company, including its
subsidiaries, is made known to the principal executive officer and the principal financial officer. To the extent applicable to the Registration Statement, in the Time of Sale Prospectus and in the Prospectus, the Company has utilized such controls
and procedures in preparing and evaluating the disclosures in the Registration Statement, in the Time of Sale Prospectus and in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(pp) (A) To the knowledge of the Company, no &#147;prohibited transaction&#148; as defined under Section&nbsp;406 of ERISA or
Section&nbsp;4975 of the Code and not exempt under ERISA Section&nbsp;408 and the regulations and published interpretations thereunder has occurred with respect to any Employee Benefit Plan. No Employee Benefit Plan subject to Part 3 of Subtitle B
of Title I of ERISA, Title IV of ERISA, or Section&nbsp;412 of the Code or any &#147;multiemployer plan&#148; as defined in Section&nbsp;3(37) of ERISA or any multiple employer plan for which the Company or any ERISA Affiliate has incurred or would
reasonably be expected to incur a liability under Section&nbsp;4063 or 4064 of ERISA. No </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Employee Benefit Plan provides retiree health, life insurance, or other retiree welfare benefits except as may be required by the Consolidated Omnibus Budget Reconciliation Act of 1985, as
amended, or similar state law. Each Employee Benefit Plan is and has been operated in material compliance with its terms and all applicable laws, including but not limited to ERISA and the Code and, to the knowledge of the Company, no event has
occurred (including a &#147;reportable event&#148; as such term is defined in Section&nbsp;4043 of ERISA) and no condition exists that would subject the Company or any ERISA Affiliate to any material tax, fine, lien, penalty or liability imposed by
ERISA, the Code or other applicable law. Each Employee Benefit Plan intended to be qualified under Code Section&nbsp;401(a) is so qualified and has a favorable determination or opinion letter from the IRS upon which it can rely, and any such
determination or opinion letter remains in effect and has not been revoked; to the knowledge of the Company, nothing has occurred since the date of any such determination or opinion letter that is reasonably likely to affect such qualification;
(B)&nbsp;the Company does not have any Foreign Benefit Plans, (C)&nbsp;the Company does not have any obligations under any collective bargaining agreement with any union and, to the knowledge of the Company, no organization efforts are underway with
respect to Company employees. As used in this Agreement, &#147;<B>Code</B>&#148; means the Internal Revenue Code of 1986, as amended; &#147;<B>Employee Benefit Plan</B>&#148; means any &#147;employee benefit plan&#148; within the meaning of
Section&nbsp;3(3) of ERISA, including, without limitation, all stock purchase, stock option, stock-based severance, employment, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control,</FONT></FONT> medical, disability,
fringe benefit, bonus, incentive, deferred compensation, employee loan and all other employee benefit plans, agreements, programs, policies or other arrangements, whether or not subject to ERISA, under which (1)&nbsp;any current or former employee,
director or independent contractor of the Company or its subsidiaries has any present or future right to benefits and which are contributed to, sponsored by or maintained by the Company or any of its respective subsidiaries or (2)&nbsp;the Company
or any of its subsidiaries has had or has any present or future obligation or liability; &#147;<B>ERISA</B>&#148; means the Employee Retirement Income Security Act of 1974, as amended; &#147;<B>ERISA Affiliate</B>&#148; means any member of the
company&#146;s controlled group as defined in Code Section&nbsp;414(b), (c), (m) or (o); and &#147;<B>Foreign Benefit Plan</B>&#148; means any Employee Benefit Plan established, maintained or contributed to outside of the United States or which
covers any employee working or residing outside of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(qq) No labor dispute with the employees of the
Company or any of its subsidiaries exists or, to the knowledge of the Company, is threatened or imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its subsidiaries&#146; principal
suppliers, contractors or customers, that would reasonably be expected to result in a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(rr) No forward-looking statement (within the meaning of Section&nbsp;27A of the Act and Section&nbsp;21E of the Exchange Act)
contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <I>Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several Underwriters, and each
Underwriter, upon the basis of the representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective numbers of Firm Shares set
forth in Schedule I hereto opposite its name at $9.89625 a share (the &#147;<B>Purchase Price</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the basis of
the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not
jointly, up to 2,145,000 Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional Shares shall be reduced by an amount per share equal to any dividends declared by the Company and
payable on the Firm Shares but not payable on such Additional Shares. The Representatives may exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written notice not later than 30 days after the date of
this Agreement. Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase date must be at least one business day after the written
notice is given and may not be earlier than the closing date for the Firm Shares or later than ten business days after the date of such notice. On each day, if any, that Additional Shares are to be purchased (an &#147;<B>Option Closing
Date</B>&#148;), each Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the
total number of Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set forth in Schedule I hereto opposite the name of such Underwriter bears to the total number of Firm Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <I>Terms of Public Offering</I>. The Company is advised by the Representatives that the Underwriters propose to make a
public offering of their respective portions of the Shares as soon after this Agreement has become effective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and as in the Representatives&#146; judgment is advisable. The Company is further advised by the Representatives that the Shares are to be offered to the public initially at $10.50 a share (the
&#147;<B>Public Offering Price</B>&#148;) and to certain dealers selected by Morgan Stanley at a price that represents a concession not in excess of $0.36225 a share under the Public Offering Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <I>Payment and Delivery. </I>Payment for the Firm Shares shall be made to the Company in Federal or other funds immediately
available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on October 27, 2023, or at such other time on the same or such other date, not later than
November&nbsp;3, 2023, as shall be designated in writing by the Representatives. The time and date of such payment are hereinafter referred to as the &#147;<B>Closing Date</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payment for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York
City against delivery of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section&nbsp;2 or at such other time on the
same or on such other date, in any event not later than December&nbsp;7, 2023, as shall be designated in writing by the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Firm Shares and Additional Shares shall be registered in such names and in such denominations as the Representatives shall
request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares and Additional Shares shall be delivered to the Representatives on the Closing Date or an
Option Closing Date, as the case may be, for the respective accounts of the several Underwriters, with any transfer taxes payable in connection with the transfer of the Shares to the Underwriters duly paid, against payment of the Purchase Price
therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <I>Conditions to the Underwriters&#146; Obligations</I>. The obligations of the Company to sell the Shares
to the Underwriters and the several obligations of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) no order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding
for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) there shall not have occurred any change, or any development involving a prospective change, in the
condition, financial or otherwise, or in the earnings, business, operations or prospects of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus that, in the judgment of the Representatives, is
material and adverse and that makes it, in the judgment of the Representatives, impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The Underwriters shall have received on the Closing Date: (i)&nbsp;a certificate, dated the Closing Date and signed by an
executive officer of the Company, to the effect set forth in Sections 5(a)(i) and 5(a)(ii) above and to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and
that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date and (ii)&nbsp;a certificate signed by the Company&#146;s Chief Financial
Officer, dated the respected dates of delivery thereof and addressed to the Representatives, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The officer signing and delivering such certificate on behalf of the Company may rely upon his or her knowledge as to
proceedings threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The Underwriters shall have received on the Closing Date an opinion and a negative assurance
letter of Dentons Durham Jones Pinegar P.C., outside counsel for the Company, dated the Closing Date, in each case in form and substance reasonably satisfactory to the Representatives, together with signed or reproduced copies of such letter for
each of the other Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) The Underwriters shall have received on the Closing Date an opinion of Dentons Durham
Jones Pinegar P.C., intellectual property counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other
Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) The Underwriters shall have received on the Closing Date an opinion and
a negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Underwriters, dated the Closing Date, in the form mutually agreed upon between the Representatives and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to the negative assurance letter to be delivered pursuant to Section&nbsp;5(c) and 5(e) above, Dentons
Durham Jones Pinegar P.C. and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. may state that their opinions and beliefs are based upon their participation in the preparation of the Registration Statement, the Time of Sale Prospectus, the
Prospectus and any amendments or supplements thereto and review and discussion of the contents thereof, but are without independent check or verification, except as specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) The Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or
the Closing Date, as the case may be, in form and substance satisfactory to the Underwriters, from Deloitte&nbsp;&amp; Touche LLP, independent public accountants, containing statements and information of the type ordinarily included in
accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; <I>provided</I> that
the letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of <U>Exhibit
A</U> hereto, between the Representatives and certain shareholders, officers and directors of the Company relating to restrictions on sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to the
Representatives on or before the date hereof, shall be in full force and effect on the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) The several
obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to the Representatives on the applicable Option Closing Date of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) a certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming
that the certificate delivered on the Closing Date pursuant to Section&nbsp;5(b)(i) hereof remains true and correct as of such Option Closing Date and a certificate, dated the Option Closing Date and signed by the Chief Financial Officer of the
Company. Confirming that the certificate delivered on the Closing Date pursuant to Section&nbsp;5(b)(ii) hereof remains true and correct as of such Option Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) an opinion and negative assurance letter of Dentons Durham Jones Pinegar P.C., outside counsel for the
Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(c) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) an opinion of Dentons Durham Jones Pinegar P.C., intellectual property counsel for the Company, dated the
Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(d) hereof </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) an opinion and negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel
for the Underwriters, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(e) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) a letter dated the Option Closing Date, in form and substance satisfactory to the Underwriters, from
Deloitte&nbsp;&amp; Touche LLP, independent public accountants, substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section&nbsp;5(f) hereof; <I>provided</I> that the letter delivered on the Option
Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than two business days prior to such Option Closing Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) such other documents as the Representatives may reasonably request with respect to the good standing of
the Company, the due authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <I>Covenants of the Company</I>. The Company covenants with each Underwriter as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) To furnish to the Representatives, without charge, six signed copies of the Registration Statement (including exhibits
thereto and documents incorporated by reference) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto but including documents incorporated by reference) and to furnish to the
Representatives in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section&nbsp;6(e) or 6(f) below, as many copies of the Time of
Sale Prospectus, the Prospectus, any documents incorporated by reference therein and any supplements and amendments thereto or to the Registration Statement as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Before amending or supplementing the Registration Statement, the Time of
Sale Prospectus or the Prospectus, to furnish to the Representatives a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which the Representatives reasonably object, and to file with the
Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) To furnish to the Representatives a copy of each proposed free writing prospectus to be prepared by or on behalf of, used
by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which the Representatives reasonably object. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Not to take any action that would result in an Underwriter or the Company being required to file with the Commission
pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet
available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances, not
misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file, or if, in the reasonable opinion of counsel for the
Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request,
either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to a
prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) If, during such period after the first date of the public offering of the Shares as in the opinion of
counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or condition
exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the
Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file with the Commission
and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses the Representatives will furnish to the Company) to which Shares may have been sold by the Representatives on behalf of the Underwriters and to any
other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice
referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the
Underwriters shall reasonably request, provided that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so
qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) To make generally available to the Company&#146;s security holders and to the Representatives as soon as practicable an
earnings statement covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the
rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Whether or not the transactions contemplated in this Agreement
are consummated or this Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i)&nbsp;the fees, disbursements and expenses of the Company&#146;s counsel and
the Company&#146;s accountants in connection with the registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary
prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated
therewith, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii)&nbsp;all costs and expenses related to the transfer and delivery of
the Shares to the Underwriters, including any transfer or other taxes payable thereon, (iii)&nbsp;the cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares under state
securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities laws as provided in Section&nbsp;6(g) hereof, including filing fees and the reasonable fees and disbursements of counsel
for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum (such fees and expenses of counsel in an aggregate amount not to exceed $5,000), (iv) all filing fees and the reasonable
fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering of the Shares by the Financial Industry Regulatory Authority (<I>provided</I>, that the amount payable by the Company with
respect to fees and disbursements of counsel for the Underwriters pursuant to subsections (iii)&nbsp;and (iv) shall not exceed $30,000), (v) all costs and expenses incident to listing the Shares on Nasdaq Global Select Market, (vi)&nbsp;the cost of
printing certificates representing the Shares, (vii)&nbsp;the costs and charges of any transfer agent, registrar or depositary, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148;
undertaken in connection with the marketing of the offering of the Shares (with the Underwriters agreeing to pay all costs and expenses related to their participation in investor presentations or any &#147;road show&#148; undertaken in connection
with the marketing of the offering of the Shares), including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees
and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and 50% of ground
transportation costs and 50% of the cost of any aircraft chartered in connection with the road show (the remaining 50% of the cost of such ground transportation and aircraft to be paid by the Underwriters), (ix) the document production charges and
expenses associated with printing this Agreement and (x)&nbsp;all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood, however,
that except as provided in this Section, Section&nbsp;8 entitled &#147;Indemnity and Contribution&#148; and the last paragraph of Section&nbsp;10 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of
their counsel, stock transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any offers they may make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) If at any time following the distribution of any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act there occurred or occurs an event or development
as a result of which such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own
expense, such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) The Company will deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly
completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company undertakes to provide such additional supporting documentation as each Underwriter may
reasonably request in connection with the verification of the foregoing Certification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company also covenants with
each Underwriter that, without the prior written consent of the Representatives on behalf of the Underwriters, it will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of the Prospectus (the
&#147;<B>Restricted Period</B>&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or
dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause 1 or 2 above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3)&nbsp;file any
registration statement with the Commission relating to the offering of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock. The restrictions contained in the foregoing sentence shall not
apply to (A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;the issuance by the Company of shares of Common Stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof as described in each of the
Time of Sale Prospectus and Prospectus, (C)&nbsp;grants of options, restricted stock, restricted stock units or other equity awards and the issuance of Common Stock or securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
convertible into or exercisable for Common Stock (whether upon the exercise of stock options or otherwise) to employees, officers, directors, advisors, or consultants of the Company pursuant to
the terms of a plan in effect on the date hereof and as described in each of the Time of Sale Prospectus and Prospectus, (D)&nbsp;the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> to register Common Stock
issuable pursuant to any employee benefit plans, qualified stock option plans or other employee compensation plans, described in the Time of Sale Prospectus, (E)&nbsp;Common Stock or any securities convertible into, or exercisable or exchangeable
for, Common Stock, or the entry into an agreement to issue Common Stock or any securities convertible into, or exercisable or exchangeable for, Common Stock, in connection with any merger, joint venture, strategic alliances, commercial or other
collaborative transaction or the acquisition or license of the business, property, technology or other assets of another individual or entity or the assumption of an employee benefit plan in connection with a merger or acquisition (including the
filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or other appropriate form with respect thereto), <I>provided</I> that the aggregate number of shares of Common Stock or securities convertible into, exercisable
or exchangeable for Common Stock (on an <FONT STYLE="white-space:nowrap">as-converted,</FONT> <FONT STYLE="white-space:nowrap">as-exercised</FONT> or <FONT STYLE="white-space:nowrap">as-exchanged</FONT> basis, as the case may be) that the Company
may sell or issue pursuant to this clause (E)&nbsp;shall not exceed 5% of the total number of shares of the Company&#146;s Common Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement
(determined on a fully diluted basis and as adjusted for stock splits, stock dividends and other similar events after the date hereof); and <I>provided further</I>, that the recipients of any shares of Common Stock issued pursuant to this clause
(E)&nbsp;during the Restricted Period shall enter into an agreement substantially in the form of Exhibit A hereto on or prior to such issuance, or (F)&nbsp;facilitating the establishment of a trading plan on behalf of a shareholder, officer or
director of the Company pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, for the transfer of shares of Common Stock, <I>provided</I> that (i)&nbsp;such plan does not provide for the transfer of Common Stock
during the Restricted Period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing shall
include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <I>Covenants of the Underwriters</I>. Each Underwriter, severally and not jointly, covenants with the Company not to take
any action that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by the Company
thereunder, but for the action of the Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <I>Indemnity and Contribution.</I> (a)&nbsp;The Company agrees to
indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate of any Underwriter within
the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any
such action or claim) that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus
or any amendment or supplement thereto, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities
Act, any &#147;road show&#148; as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;), the Prospectus or any amendment or supplement thereto, or any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of, or are based upon, any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any such untrue statement or omission or alleged untrue statement or omission made in reliance
upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information
furnished by the Underwriters through the Representatives consists of the information described as such in paragraph (b)&nbsp;below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its
officers who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the foregoing indemnity
from the Company to such Underwriter, but only with reference to information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, any
preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show, or the Prospectus or any amendment or supplement thereto, provided that the only such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the third and twelfth paragraphs under the caption
&#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) In case any proceeding (including any governmental investigation) shall be instituted
involving any person in respect of which indemnity may be sought pursuant to Section&nbsp;8(a) or 8(b), such person (the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such indemnity may be sought (the
&#147;<B>indemnifying party</B>&#148;) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the
indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and
expenses of such counsel shall be at the expense of such indemnified party unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii)&nbsp;the named parties to any such
proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It
is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one
separate firm (in addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Representatives, in the case of parties
indemnified pursuant to Section&nbsp;8(a), and by the Company, in the case of parties indemnified pursuant to Section&nbsp;8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent,
but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the
foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the
indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid
request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified
party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an
unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) To the extent the indemnification provided for in Section&nbsp;8(a) or 8(b) is unavailable to an indemnified party or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable
by such indemnified party as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from
the offering of the Shares or (ii)&nbsp;if the allocation provided by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 8(d)(i) above but
also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the
offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover of the Prospectus, bear to the
aggregate Public Offering Price of the Shares. The relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;8 are several in proportion to the respective number of Shares they have purchased hereunder, and not joint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this
Section&nbsp;8 were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in Section&nbsp;8(d). The amount paid or payable by an indemnified party as a
result of the losses, claims, damages and liabilities referred to in Section&nbsp;8(d) shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending any such action or claim. Notwithstanding the provisions of this Section&nbsp;8, no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares
underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies
provided for in this Section&nbsp;8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) The indemnity and contribution provisions contained in this Section&nbsp;8 and the representations, warranties and other
statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Underwriter, any person
controlling any Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <I>Termination</I>. The Underwriters may terminate this Agreement by notice given by the Representatives to the Company, if
after the execution and delivery of this Agreement and prior to or on the Closing Date or any Option Closing Date, as the case may be, (i)&nbsp;trading generally shall have been suspended or materially limited on, or by, as the case may be, either
of the New York Stock Exchange or the Nasdaq Global Select Market (ii)&nbsp;trading of any securities of the Company shall have been suspended on any exchange or in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, (iii)&nbsp;a material disruption in securities settlement, payment or clearance services in the United States shall have occurred, (iv)&nbsp;any
moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v)&nbsp;there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any calamity or
crisis that, in the judgment of the Representatives, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in the judgment of the Representatives, impracticable or inadvisable to proceed
with the offer, sale or delivery of the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus or the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <I>Effectiveness; Defaulting Underwriters</I>. This Agreement shall become effective upon the execution and delivery
hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of
the Underwriters shall fail or refuse to purchase Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to
purchase is not more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set
forth opposite their respective names in Schedule I bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as the
Representatives may specify, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; <I>provided</I> that in no event shall the number of Shares that any Underwriter has agreed
to purchase pursuant to this Agreement be increased pursuant to this Section&nbsp;10 by an amount in excess of <FONT STYLE="white-space:nowrap">one-ninth</FONT> of such number of Shares without the written consent of such Underwriter. If, on the
Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the
aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall terminate
without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company. In any such case either the Representatives or the Company shall have the right to postpone the Closing Date, but in no event for
longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected. If, on an Option Closing Date, any
Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs is more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate
number of Additional Shares to be purchased on such Option Closing Date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall have the option to (i)&nbsp;terminate their obligation hereunder to purchase the Additional Shares
to be sold on such Option Closing Date or (ii)&nbsp;purchase not less than the number of Additional Shares that such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Underwriters would have been obligated to purchase in the absence of such default. Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of
any default of such Underwriter under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If this Agreement shall be terminated by the Underwriters, or any
of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement,
the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses (including the reasonable fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <I>Entire Agreement</I>. (a)&nbsp;This Agreement, together with any contemporaneous written agreements and any prior
written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and the Underwriters with respect to the preparation of any preliminary prospectus,
the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)
The Company acknowledges that in connection with the offering of the Shares: (i)&nbsp;the Underwriters have acted at arm&#146;s length, are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii)&nbsp;the Underwriters
owe the Company only those duties and obligations set forth in this Agreement, any contemporaneous written agreements and prior written agreements (to the extent not superseded by this Agreement), if any, (iii)&nbsp;the Underwriters may have
interests that differ from those of the Company, and (iv)&nbsp;none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the
Underwriters with respect to any entity or natural person. The Company waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the
offering of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <I>Recognition of the U.S. Special Resolution Regimes</I>. (a)&nbsp;In the event that any
Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the
same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this Section a &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148;
in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &#167; 382.2(b). &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#147;<B>U.S. Special Resolution
Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. <I>Counterparts</I>. This Agreement may be signed in two or more counterparts, each of which shall be an original,
with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com or www.echosign.com) or other transmission method of any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. <I>Applicable Law</I>. This Agreement shall be governed by and construed in accordance with the internal laws of the State
of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. <I>Headings</I>. The headings of the sections of this Agreement have been inserted for convenience of
reference only and shall not be deemed a part of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. <I>Notices. </I>All communications hereunder shall be in writing and
effective only upon receipt and if to the Underwriters shall be delivered, mailed or sent to Morgan Stanley&nbsp;&amp; Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department, and Cowen
and Company, LLC, 599 Lexington Avenue, 25th Floor, New York, New York 10022, Attention: Head of Equity Capital Markets, Fax: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-562-1249,</FONT></FONT> with a copy to the General
Counsel, Fax: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-562-1130,</FONT></FONT> and Barclays Capital Inc., 745 Seventh Avenue, New York, NY 10019, Attention: Syndicate Registration, Fax: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">646-834-8133,</FONT></FONT> with a copy to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111, Attention: John T. Rudy; and if to the Company shall be delivered, mailed
or sent to Alphatec Holdings, Inc., 5818 El Camino Real, Carlsbad, California 92008, Attention: Tyson Marshall, Associate General Counsel, email: tmarshall@atecspine.com with a copy to Dentons Durham Jones Pinegar P.C., 192 E. 200 N., Third Floor,
St. George, Utah 84770, Attention: Joshua E. Little, email: joshua.e.little@dentons.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Pages Follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ALPHATEC HOLDINGS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ J. Todd Koning</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: J. Todd Koning</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: Chief Financial Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Accepted as of the date hereof</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MORGAN STANLEY&nbsp;&amp; CO. LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">COWEN AND COMPANY, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BARCLAYS CAPITAL INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acting severally on behalf of themselves and the several</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Underwriters named in Schedule I hereto.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MORGAN STANLEY&nbsp;&amp; CO. LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Eduardo Herdan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Eduardo Herdan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: Vice President</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">COWEN AND COMPANY, LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Michael Campbell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Michael Campbell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BARCLAYS CAPITAL INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Dan Cocks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Dan Cocks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: Managing Director</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Firm&nbsp;Shares&nbsp;To<BR>Be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,720,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,575,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,575,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,430,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Time of Sale Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Preliminary Prospectus issued October&nbsp;24, 2023 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Free writing prospectuses filed by the Company under Rule 433(d) of the Securities Act:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Pricing information: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Number of Firm shares purchased by the Underwriters from the Company: 14,300,000 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Number of Additional Shares to be sold by the Company at the option of the Underwriters: 2,145,000 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Initial price per share to the public: $10.50 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">_____________, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan
Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Barclays Capital Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c/o
Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1585 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10036 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c/o Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">599 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c/o Barclays Capital Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">745 Seventh Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned understands that Morgan Stanley&nbsp;&amp; Co. LLC (&#147;<B>Morgan Stanley</B>&#148;), Cowen and Company, LLC
(&#147;<B>Cowen</B>&#148;), and Barclays Capital Inc, (&#147;<B>Barclays</B>&#148;) (collectively, the &#147;<B>Representatives</B>&#148;) propose to enter into an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) with Alphatec
Holdings, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), providing for the public offering (the &#147;<B>Public Offering</B>&#148;) by the several Underwriters, including the Representatives (the &#147;<B>Underwriters</B>&#148;), of
shares (the &#147;<B>Shares</B>&#148;) of the common stock, $0.0001 par value of the Company (the &#147;<B>Common Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public
Offering, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, it will not, and will not publicly disclose an intention to, during the period commencing on the date hereof and
ending 90 days after the date of the final prospectus (the &#147;<B>Restricted Period</B>&#148;) relating to the Public Offering (the &#147;<B>Prospectus</B>&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock
or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock so owned, whether any such transaction described in clause (1)&nbsp;or (2) above
is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a)&nbsp;transactions relating to shares of Common Stock or other securities acquired in open market transactions
after the completion of the Public Offering, <I>provided</I> that no filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other securities acquired
in such open market transactions, (b)&nbsp;transfers of shares of Common Stock or any security convertible into Common Stock (i)&nbsp;as a bona fide gift, (ii)&nbsp;to any trust for the direct or indirect benefit of the undersigned or the immediate
family of the undersigned, (iii)&nbsp;if the undersigned is a corporation, partnership, limited liability company, trust or other business entity (1)&nbsp;transfers to another corporation, partnership, limited liability company, trust or other
business entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or (2)&nbsp;distributions of shares of Common Stock or any security convertible into or
exercisable for Common Stock to limited partners, limited liability company members or stockholders of the undersigned, (iv)&nbsp;if the undersigned is a trust, transfers to the beneficiary of such trust, or (v)&nbsp;transfers by testate succession
or intestate succession; <I>provided</I> that in the case of any transfer or distribution pursuant to clause (b), (x) such transfer shall not involve a disposition for value, (y)&nbsp;each donee or distributee shall sign and deliver a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of this agreement and (z)&nbsp;no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if any such filing, report or
announcement shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the circumstances of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
transfer or distribution, or (c)&nbsp;(i) the exercise of stock options granted pursuant to the Company&#146;s equity incentive plans described in the Time of Sale Prospectus or the Prospectus
and outstanding as of the date of the Prospectus; provided (x)&nbsp;that it shall apply to any of the undersigned&#146;s Common Stock issued upon such exercise (y)&nbsp;any filing under Section&nbsp;16 of the Exchange Act made during the Restricted
Period shall clearly indicate that (A)&nbsp;the filing relates to the circumstances described in this clause (c)(i) and (B)&nbsp;no Common Stock was sold by the undersigned and (z)&nbsp;the undersigned does not otherwise voluntarily effect any
public filing or report regarding such sales or transfers during the Restricted Period, (ii)&nbsp;the establishment of any contract, instruction or plan (a &#147;<B><FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan</B>&#148;) that satisfies all of
the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act; <I>provided</I> that no sales of the undersigned&#146;s Common Stock shall be made pursuant to such a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan
prior to the expiration of the Restricted Period, and to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of
such plan, such announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan during the Restricted Period or (iii)&nbsp;sales pursuant to
the terms of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan existing on the date hereof; <I>provided</I> that (x)&nbsp;any filing under Section&nbsp;16 of the Exchange Act made during the Restricted Period shall state that such sales have
been executed under a&nbsp;10b5-1&nbsp;Trading Plan and shall also state the date such&nbsp;10b5-1&nbsp;Trading Plan was adopted and (y)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such sales or
transfers during the Restricted Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned acknowledges and agrees that the foregoing precludes the
undersigned from engaging in any hedging or other transactions designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition of any shares of Common Stock, or securities convertible into or exercisable or
exchangeable for Common Stock, even if any such sale or disposition transaction or transactions would be made or executed by or on behalf of someone other than the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned understands that the Company and the Underwriters are relying upon this agreement in proceeding toward
consummation of the Public Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned further acknowledges and agrees that none of the Underwriters has made any recommendation or provided any
investment or other advice to the undersigned with respect to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting, financial, regulatory, tax and
other advisors with respect to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. The undersigned further acknowledges and agrees that, although the
Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to it in connection with the Public Offering, the Underwriters are not making a recommendation to it to participate in the Public
Offering or sell any Shares at the price determined in the Public Offering, and nothing set forth in such disclosures or documentation is intended to suggest that any Underwriter is making such a recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public
Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned understands that the undersigned shall be released from all obligations under this Agreement if (i)&nbsp;the
Company notifies the Representatives in writing that it does not intend to proceed with the Public Offering, (ii)&nbsp;termination of the Underwriting Agreement prior to payment for and delivery of the Common Stock to be sold thereunder, or
(iii)&nbsp;the Public Offering is not completed by November&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This agreement shall be governed by and
construed in accordance with the laws of the State of New York. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(Name)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(Address)</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>d574137dex12.htm
<DESCRIPTION>EX-1.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.2 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALPHATEC HOLDINGS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT TO UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">October&nbsp;26, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan
Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Barclays Capital Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Morgan Stanley&nbsp;&amp; Co. LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1585 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10036 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Cowen and Company, LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">599 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">c/o</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Barclays Capital Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">745 Seventh Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This letter serves as an amendment (the &#147;<U>First Amendment</U>&#148;) to the Underwriting Agreement (the
&#147;<U>Underwriting Agreement</U>&#148;), dated October&nbsp;24, 2023, by and between Alphatec Holdings, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;) and Morgan Stanley&nbsp;&amp; Co. LLC (&#147;Morgan Stanley&#148;), Cowen and
Company, LLC (&#147;Cowen&#148;), and Barclays Capital Inc. (&#147;Barclays&#148;), acting as the representatives (the &#147;<U>Representatives</U>&#148;) of the several Underwriters named in <U>Schedule I</U> thereto (the
&#147;<U>Underwriters</U>,&#148; or each, an &#147;<U>Underwriter</U>&#148;). Capitalized terms not defined herein shall have the meanings ascribed to them in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The terms of our agreement, as set forth in the Underwriting Agreement, are hereby modified and amended as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The first paragraph of Section&nbsp;2 of the Underwriting Agreement is deleted and replaced in its entirety with the following:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the
representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective numbers of Firm Shares set forth in Schedule I hereto
opposite its name at $9.8847 a share (the &#147;<B>Purchase Price</B>&#148;).&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">****** </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as specifically set forth herein, all other terms of the Underwriting Agreement shall remain in full force and effect
without modification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ALPHATEC HOLDINGS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ J. Todd Koning</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">J. Todd Koning</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Financial Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accepted as of the date first above written </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>MORGAN STANLEY&nbsp;&amp; CO. LLC</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>COWEN AND COMPANY, LLC</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>BARCLAYS CAPITAL INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acting severally on behalf of themselves and the several</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Underwriters named in Schedule I to the Underwriting</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Agreement.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MORGAN STANLEY&nbsp;&amp; CO. LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Chris Rigoli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Chris Rigoli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:&#8194; Executive Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">COWEN AND COMPANY, LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Michael Campbell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Michael Campbell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:&#8194; Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BARCLAYS CAPITAL INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Dan Cocks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Dan Cocks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: Managing Director</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page &#150;
First Amendment to Underwriting Agreement] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d574137dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g574137g1025102034721.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">Dentons Durham Jones Pinegar P.C.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">192 East 200 North, Third Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">St. George, Utah
84770</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">United States</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="right">dentons.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">October&nbsp;26, 2023 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Alphatec Holdings, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">1950 Camino Vida Roble</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Carlsbad, CA 92008 <BR></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><U>Alphatec Holdings, Inc. &#150; Registration Statement of Form <FONT STYLE="white-space:nowrap">S-3ASR</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In our capacity as counsel to Alphatec
Holdings, Inc., a corporation organized under the laws of the State of Delaware (the &#147;Company&#148;), we have been asked to render this opinion in connection with a registration statement on <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Form&nbsp;S-3ASR&nbsp;(File&nbsp;No.&nbsp;333-271336)&nbsp;(as</FONT></FONT> amended or supplemented, the &#147;Registration Statement&#148;), which registration statement was initially filed by the Company with the
Securities and Exchange Commission (the &#147;Commission&#148;) and became automatically effective on April&nbsp;19, 2023, as supplemented by the prospectus supplement filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), dated October&nbsp;24, 2023 (the &#147;Prospectus Supplement&#148;), under which up to 16,445,000 shares (the &#147;Shares&#148;) of Company common stock, par value $0.0001 per share, are being sold by the Company
pursuant to the Underwriting Agreement, dated October&nbsp;24, 2023, between the Company and the underwriters named therein. The Shares include an option granted to the underwriters of the offering to purchase up to an additional 2,145,000 Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are delivering this opinion to you at your request in accordance with the requirements of Item 16 of
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;and</FONT> Item 601(b)(5) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K&nbsp;under</FONT> the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In
connection with rendering this opinion, we have examined originals, certified copies or copies otherwise identified as being true copies of the following: (i)&nbsp;the Company&#146;s amended and restated certificate of incorporation, (ii)&nbsp;the
Company&#146;s restated bylaws, (iii)&nbsp;the Registration Statement, including the prospectus contained therein (the &#147;Base Prospectus&#148;), (iv) the Prospectus Supplement (the Base Prospectus and the Prospectus Supplement are collectively
referred to herein as the &#147;Prospectus&#148;), (v) corporate proceedings of the Company relating to the Shares and (vi)&nbsp;such other instruments and documents as we have deemed relevant under the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In making the aforesaid examinations, we have assumed the genuineness and authenticity of all documents examined by us and all signatures thereon, and the conformity to
originals of all copies of all documents examined by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Based on the foregoing, and in reliance thereon, and subject to the qualifications, limitations and
exceptions stated herein, we are of the opinion that the Shares have been duly authorized and, when issued and delivered by the Company against due payment therefor in accordance with the terms set forth in the Registration Statement and the
Prospectus, will be validly issued, fully paid <FONT STYLE="white-space:nowrap">and&nbsp;non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The foregoing opinion is limited to the laws of the
State of Delaware (excluding local laws) and the federal law of the United States of America. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g574137g1025102034490.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Alphatec Holdings, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">October 26, 2023</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Page 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">dentons.com</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We hereby consent to the use of our opinion as Exhibit 5.1 to the Registration Statement and to the reference to this
firm and this opinion under the heading &#147;Legal Matters&#148; in the Prospectus comprising a part of the Registration Statement and any amendment thereto. In giving such consent, we do not hereby admit that we come within the category of persons
whose consent is required under Section&nbsp;7 of the Act, or the rules and regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">/s/ Dentons Durham Jones Pinegar P.C.</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d574137dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATEC Announces Pricing of Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>CARLSBAD, California, October</B><B></B><B>&nbsp;24, 2023 </B>&#150; Alphatec Holdings, Inc. (&#147;ATEC&#148;) (NASDAQ: ATEC), a provider
of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of an underwritten public offering of 14,300,000 shares of its common stock at a public offering price of&nbsp;$10.50 per share. The
offering is expected to close on October&nbsp;27, 2023, subject to the satisfaction of customary closing conditions. In connection with the offering, ATEC has granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to
purchase up to an additional 2,145,000 shares of common stock in the offering at the public offering price, less underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan Stanley, TD Cowen, Barclays and Stifel are acting as joint book-running managers in the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ATEC expects to receive gross proceeds from the offering of approximately&nbsp;$150&nbsp;million, assuming no exercise of the
underwriters&#146; option to purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of common stock are being offered pursuant to a shelf registration
statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-271336)</FONT> previously filed with and declared effective by the&nbsp;Securities and Exchange Commission (the &#147;SEC&#148;). A
preliminary prospectus supplement and accompanying base prospectus relating to the offering, and a final prospectus supplement and accompanying base prospectus relating to the offering each contain important information relating to the ATEC&#146;s
shares of common stock. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC&#146;s website at www.sec.gov. The final prospectus supplement and
accompanying base prospectus will be filed with the&nbsp;SEC&nbsp;and available on the SEC&#146;s website thereafter, and, when available, may also be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014; Cowen and Company, LLC, 599 Lexington Avenue, New York, New York 10022, by telephone at (833) <FONT STYLE="white-space:nowrap">297-2926</FONT> or by email at prospectus_ecm@cowen.com; or Barclays Capital Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-888-603-5847</FONT></FONT></FONT> or by email at
barclaysprospectus@broadridge.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor
shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>About ATEC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ATEC, through
its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC&#146;s Organic Innovation
Machine<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> is focused on developing new approaches that integrate seamlessly with the Company&#146;s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly
achieve the goals of spine surgery. ATEC&#146;s vision is to be the Standard Bearer in Spine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainty. Such statements are based on management&#146;s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the
forward-looking statements. ATEC cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various
factors. The words &#147;believe,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;look forward&#148; and &#147;anticipate,&#148; variations of such words and similar expressions
identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. Forward-looking statements include, but are not limited to, the Company&#146;s expectations regarding the completion, timing
and size of the proposed public offering. Important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to, risks and uncertainties related
to market and other conditions and the satisfaction of customary closing conditions related to the proposed public offering.&nbsp;A further list and description of these and other factors, risks and uncertainties can be found in ATEC&#146;s most
recent annual report, any subsequent quarterly and current reports, and certain other filings, filed with the SEC. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Company Contact: </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">J. Todd Koning </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">investorrelations@atecspine.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Investor/Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tina Jacobsen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(760) <FONT STYLE="white-space:nowrap">494-6790</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">investorrelations @atecspine.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>atec-20231024.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/27/2023 1:28:51 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:atec="http://alphatecspine.com/20231024"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://alphatecspine.com/20231024"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atec-20231024_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atec-20231024_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>atec-20231024_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/27/2023 1:28:52 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>atec-20231024_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/27/2023 1:28:52 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="atec-20231024.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g574137g1025102034490.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g574137g1025102034490.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  = )H# 2(  A$! Q$!_\0
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)=G%4J.;NS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g574137g1025102034721.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g574137g1025102034721.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  2 +$# 2(  A$! Q$!_\0
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2J=Q1117(<P4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139698291419792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001350653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 24,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALPHATEC HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-52024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2463898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1950 Camino Vida Roble<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">431-9286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATEC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>d574137d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atec-20231024.xsd" xlink:type="simple"/>
    <context id="duration_2023-10-24_to_2023-10-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001350653</identifier>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-24</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2023-10-24_to_2023-10-24"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2023-10-24_to_2023-10-24">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-10-24_to_2023-10-24"
      id="Hidden_dei_EntityCentralIndexKey">0001350653</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-10-24_to_2023-10-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-10-24_to_2023-10-24">2023-10-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-10-24_to_2023-10-24">ALPHATEC HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-10-24_to_2023-10-24">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-10-24_to_2023-10-24">000-52024</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-10-24_to_2023-10-24">20-2463898</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-10-24_to_2023-10-24">1950 Camino Vida Roble</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-10-24_to_2023-10-24">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-10-24_to_2023-10-24">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-10-24_to_2023-10-24">92008</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-10-24_to_2023-10-24">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-10-24_to_2023-10-24">431-9286</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-10-24_to_2023-10-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-10-24_to_2023-10-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-10-24_to_2023-10-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-10-24_to_2023-10-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-10-24_to_2023-10-24">Common stock, par value $.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-10-24_to_2023-10-24">ATEC</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-10-24_to_2023-10-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( /"+6E=ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #PBUI7)!Z;HJT   #X 0
M&@              @ ',$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " #PBUI799!YDAD!  #/ P  $P              @ &Q$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #[$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d574137d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atec-20231024.xsd</File>
    <File>atec-20231024_lab.xml</File>
    <File>atec-20231024_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d574137d8k.htm">d574137d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d574137d8k.htm": {
   "nsprefix": "atec",
   "nsuri": "http://alphatecspine.com/20231024",
   "dts": {
    "schema": {
     "local": [
      "atec-20231024.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "atec-20231024_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atec-20231024_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d574137d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2022": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "report": {
    "R1": {
     "role": "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-10-24_to_2023-10-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d574137d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-10-24_to_2023-10-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d574137d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://alphatecspine.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-23-264201-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-264201-xbrl.zip
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M<F4N>&ULU9I=C^(V%(;O5]K_X$UO6FE#",SLSJ!A5I29J5"9#P';5KU9F>0
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M:7<V<80P72DK\5=4I<T3KIO:GW-?QXO],7%IK'1%+5?V78VZJ(,1!3!@@69
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M@0  ()4" !    !D-3<T,3,W9&5X,3$N:'1M['UY<]M(LN?_C.!W0/0[0HJ
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MM_9_^1D?^C78> NS7OW&QWR;Z7A_?W]K[]GN_O[3S=", 2_ )1G$0Q 40@)
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ME;/,L^W@4.B"65%H&5$I<^\@69GTLEOC/]-!&F;Q=HL;?^);9SB;=Z1BKBW
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MHSPFMLHR,ZK8!K2>0^0OZ$4SWQ)'&JP)Z"5CD>D6D@,=%R@7B;YK>Y\P^UZ
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MIYYAC(S5*J7>Z;4.Z.X:YS9:8<@]Q\;/VG%4L7-#!PG>Z62<U/.W_%A"6Q!
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M,9PASA:F,=Q:D%3:3^ QB*&*86(^YED#*'G);<$_C;'6,")+19XTZ1XA&N/
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M8?;#"-\ZQ>PT^M@A"JE9@2PDN,ASL$[.E#?Z!'DXZYTPW*<!9H=AB>!%7!1
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MPA47Q#0.\>\'_K=\H?8!TMHH8:GSCCP&U?OZ!J%V4$(I]8IJ]44%'R+POQ2
M4SFP>"XEB2<DYP\Z2DCM0?WW5%SX_9XK034%3PIDK24 TI; P'_S8KY (LI-
MQ?FIC23W3LCD%4'!9B4U9W_;#]JL*I-]J/*<8 .!Q<H&L@4C6T=/2KFWS6#Z
MYID?;]GEBN9$Z!(KQ&I:9DRBZX%R43$6@#PNEEC.-"DCZT.3R(_CJZ36JZ08
M+W6ME6@:N^M]+UC^N6^TL?U>$^_(EC/'ZP6J;T*2[7%J/HX6S\ Z3@&%7AQZ
M_A*=M.!R$08B4,&6'F)+*&#!-7^'N<+=EK)<9(<WX4)'W>3PRN5Q<$9ORS-B
M.]?J)]NOA$#9K21W[TN45,"?DHR/!AAT^]=,"2(YUJ,15O'2UA.@"N<2B 5L
MFF@P.8FDPDM#4]:7XEM2%88M;TM6-Z&JH$Y4M$'B=BN'L/>K&0=0RIM[O()>
M5<17OX,WVJP&E/.RZD+AGF6-=:K,++*VF(>2:QCD=L<U,[84#Q)7*-CE.J-%
MPK,C'^P-@XE^0AF:F )/(3V,C)U".R&ARV-?>'6G4L !Z>!^Y\9AJPN_+I-Y
M%$X.FYOS+6Z+$E+Y@?PW?TIJ%3B#" .:!/,GU(BZ0N3JM]$4X&+YJ,10,).<
M^_M:\$H8DHLK2E.S\$IV"%! UQFCI& UFW[-03!SO&T!9A-M2TB*6<.2) /(
M&JH,IVH]MX4*: RB,G'9=6Y_.0A16H09<X[FE-5F:TCVE3@-I)>IXDX6YR)
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M?-?=KS>!W&QR 'WI_?YU=<G1+2Z"6TN+KR4@&*CGMA*"_$\"=K-Q32U&'?Z
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M!ALW_^(823>F#OW5R7^8,JENW$:"BZ.D)R4K@OA/!D!G_R#\H(>DR6[LB5U
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M&@CB,'"["4I%H<^7*M"NE!@-D0F<UO(M(E&!QF3\)U+$QD;Y;L].M"PQ),'
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M915\8G0(?QM1+R)%X5?6C[Y'+>__^*HK%6/JOBW.\?5__Q74P1^JWS^USD+
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M,(\>V)0-;5EL<>$2)U.&W1U\ODH]246Y5&M\3@:/F27M8N'PE'D9( X;>BB
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M.3DQ+FAT;>U:67,;-Q)^9Q7_ XK9I.RJ(46*ND6K0AV.E94EK\E-XGW9PLR
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MQ 7Y>$[:\K0&(BG)0X4W^;./4)$:"Y<GO8.R9V0H/JD,%CFEQ?J(*$9D$L9
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M@?P2UMWM'P_9C3 %T6TZISB 0AIN7M$][&W@UA')-=)HD\$\K!""B4SGKIT
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MR_8S =JH+ )/&ZJH?7?._92M*MU7YDJ<J7(:PSS S%TOR\H[$A?[$UY:-Y]
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M,#(S,3 R-%]P<F4N>&UL4$L! A0#%     @ \(M:5RAXZ5@A%   VX4   X
M             ( !]0X  &0U-S0Q,S=D.&LN:'1M4$L! A0#%     @ \(M:
M5X#03B!Z@0  ()4" !               ( !0B,  &0U-S0Q,S=D97@Q,2YH
M=&U02P$"% ,4    " #PBUI7[2^CF8$(   C0@  $               @ 'J
MI   9#4W-#$S-V1E>#$R+FAT;5!+ 0(4 Q0    ( /"+6E>0!+1&P@D  -XC
M   0              "  9FM  !D-3<T,3,W9&5X-3$N:'1M4$L! A0#%
M  @ \(M:5__P([4*"P  M2(  !$              ( !B;<  &0U-S0Q,S=D
?97@Y.3$N:'1M4$L%!@     (  @ ^@$  ,+"      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
